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Abstract: Lack of new antibiotics and increasing antimicrobi-
al resistance are among the main concerns of healthcare
communities nowadays, and these concerns necessitate the
search for novel antibacterial agents. Recently, we discov-
ered the cystobactamids—a novel natural class of antibiotics
with broad-spectrum antibacterial activity. In this work, we
describe 1) a concise total synthesis of cystobactamid 507,
2) the identification of the bioactive conformation using
noncovalently bonded rigid analogues, and 3) the first struc-
ture–activity relationship (SAR) study for cystobactamid 507
leading to new analogues with high metabolic stability, su-
perior topoisomerase IIA inhibition, antibacterial activity and,
importantly, stability toward the resistant factor AlbD.
Deeper insight into the mode of action revealed that the
cystobactamids employ DNA minor-groove binding as part
of the drug–target interaction without showing significant
intercalation. By designing a new analogue of cystobactamid
919-2, we finally demonstrated that these findings could be
further exploited to obtain more potent hexapeptides
against Gram-negative bacteria.
Introduction
The ongoing prevalence of antibiotic-resistant bacteria poses
an imminent threat to humanity.[1, 2] Therefore, the need to dis-
cover novel antibiotics with new chemical scaffolds has been
established. Nature represents a rich repository of antibiotics ;
however, the major part of these natural products (NPs) have
to be modified to optimize pharmacokinetic and pharmacody-
namic properties.[3, 4]
Recently, we reported the discovery of the cystobactamids—
a new family of antibiotics—isolated from Cystobacter sp.
(Figure 1).[5, 6] Cystobactamids (1 a–1 f) have hexapeptidic struc-
tures comprised of three p-aminobenzoic acid motifs (eastern
part) and two p-nitro/aminobenzoic acids (western part) con-
nected through different linkers. The structurally simplest natu-
ral cystobactamid 507 (2), is a tripeptide representing the east-
ern part of most of the hexapeptides (1 a–f) (Figure 1). The cys-
tobactamids display broad-spectrum antibacterial activity
Figure 1. Examples of the natural cystobactamids 1 a–f, 2.[5, 6]
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through inhibition of topoisomerases type IIA, namely DNA
gyrase and topoisomerase IV.[5] Here, we report studies on the
optimization of 2 because it is the only compound with appro-
priate physicochemical properties for oral absorption accord-
ing to Lipiniski.[7]
Results and Discussion
We used gyrase inhibition to establish the structure–activity re-
lationship (SAR), as it is the primary target of cystobactamids
in Escherichia coli.[5] The assay evaluates the effect on the DNA
supercoiling activity of gyrase using a relaxed circular plasmid
as a substrate. Cystobactamids have been shown to inhibit
gyrase similar to quinolones through stabilization of the cova-
lent enzyme–DNA complex with double-stranded DNA breaks
resulting in an accumulation of linear DNA.[5] Previously, we re-
ported that the methyl homologue 3 (Figure 2 and Table 1)
showed only a slight decrease in activity, suggesting that the
natural antibiotic 2 could be amenable to structural modifica-
tion.[8]
We therefore investigated the role of the substituents and
the conformation of 2 for activity. Replacement of the isopro-
poxy side chain in the middle ring of 2 with a methoxy group
(4) did not impact activity, whereas substitution with chlorine
(5) resulted in a significant loss of gyrase inhibition (Table 1).
This result highlights the importance of the alkoxy side chains
for ligand–target interaction. On the other hand, the isopro-
poxy of the C-terminal ring showed stronger inhibition than
the methoxy in this position (4 vs. 3), probably due to its steric
and hydrophobic properties. Consequently, we kept it in the
optimization process.
As a next step, we performed in silico conformational analy-
ses of compounds 2–4 using molecular dynamics (MD) to iden-
tify the potential conformations of the molecules and their rel-
ative energies. Generally, the compounds adopt linear confor-
mations with a backbone curvature[9] of about 1588 (Figure S31
and S32). They can adopt two constrained conformations (anti
and syn) with respect to the alkoxy side chains that are con-
trolled by the hydroxy group at the middle ring. The lowest
energy conformation is the anti form (Figure 3 A), which is sta-
bilized by three intramolecular hydrogen bonds (IMHBs). An
IMHB between C4-NH and C3-alkoxy group restricts rotation of
the C-terminal ring around the Ar-NH axis. Another IMBH be-
tween C1’-CO and C2’-OH restricts rotation of the middle ring
around the Ar-CO axis. The third IMHB between C4’-NH and
C3’-alkoxy group restricts rotation of the middle ring around
Ar-NH axis. The syn conformer is also stabilized by three IMHBs
similar to the anti form, except that C2’-OH switches from HB
donor to HB acceptor and forms a six-membered ring with C4-
NH (restricting rotation of the middle ring around the Ar-CO
axis) (Figure 3 B). The energy difference (DE) between the anti
and syn forms is 0.4–0.7 kcal mol@1. Such a minor energy differ-
ence could allow the interconversion between both conforma-
tions at ambient temperature.
We then investigated the preferred conformation for 2–4,
their esters and nitro precursors experimentally in solution by
a NOESY study in a biomimetic solvent (20 % H2O/
[D6]DMSO).
[10] In agreement with MD calculations, all com-
pounds show a strong cross-peak between C4-NH and C6’-H,
and a weak or no cross-peak with C2’-OH, indicating that these
compounds predominantly exist in the anti conformation
(Figure 4 and S8). Using standard NMR solvents, the same re-
sults were obtained (Figure S1–S10).
Subsequently, we verified whether the syn conformer could
exist under physiological conditions by a 1H NMR experiment
for the cystobactamid 507 isopropyl ester (26) at 20 and 37 8C.
We found that the chemical shift of the C2’-OH proton moved
upfield from 12.40 ppm at 20 8C (mainly HB donor form, anti)
Figure 2. General structure of cystobactamid 507 analogues.
Table 1. In vitro inhibitory activities of compounds 2–16 in the gyrase su-
percoiling assay and topoisomerase IV relaxation assay.
Compd. R1 R2 R3 R4 X IC50 gyrase [mm]
[a] IC50 topo. IV [mm]
[b]
2 iPrO OH iPrO H H 355:25 >500
3 MeO OH MeO H H 463:28 n.d.[c]
4 iPrO OH MeO H H 360:26 n.d.
5 iPrO OH Cl H H >1000 n.d.
6 iPrO MeO iPrO H H 115:18 n.d.
7 iPrO iPrO iPrO H H 60:10 175:10
8 – iPrO H – – 195:20 n.d.
9 – H iPrO – – 50:10 147:10
10 iPrO OH H H H >1000 n.d.
11 iPrO H iPrO H H 165:18 n.d.
12 iPrO H iPrO OH H 85:12 255:14
13 iPrO OH H iPrO H 101:15 n.d.
14 iPrO H iPrO OH O 110:20 n.d.
15 iPrO OH H iPrO O 106:18 n.d.
16 – – – – – 3.6 n.d.
CP[d] – – – – – 0.4:0.05 n.d.
[a] E. coli gyrase (1 unit, 20.5 nm). [b] E. coli topoisomerase IV (1 unit,
20.5 nm). [c] Not determined. [d] Ciprofloxacin.
Figure 3. Conformational analysis of cystobactamid 507 (2): A) anti form
(lowest energy conformation) ; B) syn form (DE 0.4 kcal mol@1).




to 12.35 ppm at 37 8C (pushing the conformational equilibrium
to HB acceptor form, syn) (Figure S29). In addition, we ob-
served the syn conformation in the solid state by determining
the crystal structure for the dipeptide precursor of 3 (Fig-
ure S37E), whereas in solution there was a prevalence of the
anti conformation (Figure S11). These results demonstrate that
these compounds can easily interconvert from anti to syn at
physiological temperature.
Since the anti form was the predominant conformation in
solution for 2 and all derivatives so far, we designed com-
pounds that preferentially adopt the syn form by blocking the
ambiguous hydroxy motif by methylation, thus converting it
into a HB acceptor group only (compound 6). MD calculations
indicated that 6 typically adopts an IMHB-stabilized syn confor-
mation with a large DE compared to the anti form (3.8 kcal
mol@1). NOESY studies showed a cross-peak between C4-NH
and C2’-OMe, and no cross-peak with C6’-H, indicating that the
syn conformation is predominant (Figure S15). Compound 6
showed a threefold higher activity than 2 (Table 1), indicating
that the hydroxy group is not essential for activity.
To clarify whether this enhancement was due to the induc-
tion of the syn conformation or due to an additional hydro-
phobic interaction, we first designed compound 7, bearing an
isopropoxy group in place of the methoxy (6). This modifica-
tion resulted in a six-fold improvement in activity compared to
2, indicating that, besides restricting the conformation to the
syn form, alkoxy groups at position 2 of the middle ring also
contribute to target interactions.
To investigate whether the syn conformation is a decisive
factor, we then designed two rigid cystobactamid 507 ana-
logues, 8 and 9, with a pyridine scaffold adopting only one
conformation, anti or syn, respectively (Figure 2). Rigidity was
achieved via a bifurcated IMHB between C4-NH and oxygen
atom of C3-isopropoxy as well as the nitrogen atom of the pyr-
idine ring. We confirmed the stability of 8 and 9 by MD calcu-
lations, which showed only the desired conformation in an
energy window DE of 7.0 kcal mol@1. In NOESY experiments, no
cross-peak was observed between C4-NH and pyridine C3-H at
27 8C and at higher temperatures up to 67 8C (Figure S21–S27).
Moreover, X-ray crystal structures of the compounds were as
expected (Figure 5, S37C and S37D). Results revealed that 9 is
fourfold and sevenfold more potent than 8 and 2, respectively
(Table 1), indicating that the syn form is indeed the more
active conformation of cystobactamid 507. Notably, the slightly
better activity of 8 than 2 suggests that the introduced pyri-
dine ring might contribute to the interaction with gyrase and
the inhibitory effect.
The newly designed compound 9 is clearly advantageous
compared to the natural compound 2. Introduction of a polar
pyridine ring in lieu of the benzene enhances water solubility
and ligand-lipophilicity efficiency[11] (SolpH 7.4 : 59.4 mmol mL
@1,
LLE: 3.54 for 9 vs. 9.6 mmol mL@1, 1.75 for 2, respectively). In
addition, removal of the hydroxy group, while keeping the
right conformation, increases ligand efficiency[11] (LE: 0.17 for 9
vs. 0.13 for 2). Moreover, the enhancement of the binding af-
finity of the rigid ligand 9 is at least in part due to the reduc-
tion of the unfavorable entropic contribution to the Gibbs free
energy of binding.[12]
Another important achievement could be that hopping of
the cystobactamid 507 scaffold to the novel pyridine-based
chemotype (compound 9) might circumvent the cystobacta-
mids’ cleavage through AlbD, a known resistance protein inac-
tivating the structurally related antibiotics albicidins.[13] The
AlbD endopeptidase hydrolyses the amide bond between the
middle and the N-terminal ring of the eastern part of albici-
dins/cystobactamids and the tripeptidic derivatives.[13] By incu-
bation of compound 9 with AlbD under the reported condi-
tions,[13] our hypothesis turned out to be correct ; no cleavage
of 9 in the presence of AlbD was observed (Figure 6).
For further SAR exploration, compound 2 was simplified by
omitting either the isopropoxy or the hydroxy group from the
central ring in 10 and 11, respectively (Table 1). Removal of the
former resulted in a loss of activity, emphasizing the impor-
tance of alkoxy substituents for activity. Interestingly, removing
the hydroxy group increased the activity twofold compared to
2. This confirms that the hydroxy group is not essential for ac-
tivity. Its removal permits free rotation of the middle ring, as
Figure 4. 2D-NOESY spectrum of compound 26 in a cryoprotective mixture
(20 % H2O/[D6]DMSO) adopting anti conformation.
Figure 5. X-ray crystal structures of the nitro ester precursors of 8 (93, A)
and 9 (94, B) adopting anti and syn conformation, respectively, via IMHB.




evidenced in the NOESY spectrum of 11 showing two cross-
peaks of equal intensities between C4-NH and C2’-H (syn) and
C6’-H (anti) (Figure S28).
Introduction of an isopropoxy or hydroxy group at the N-ter-
minal ring of 10 and 11, to maintain the beneficial free rota-
tion, resulted in restoration of activity with a fourfold enhance-
ment compared to 2 (13 and 12, respectively) (Table 1). These
results demonstrate the usefulness of the alkoxy motifs (2 and
13 vs. 10), and indicate that varying the distance between
them can be tolerated because of the flexibility of the new an-
alogues.
Esterification of 4 and the most potent compounds 6, 7, 9
and 11–13 decreased activity strongly, revealing that the termi-
nal carboxyl group is important for activity (Table S2). Replac-
ing the amino moiety of 12 and 13 with nitro groups, as in the
hexapeptidic cystobactamids, resulted in similar inhibitory ac-
tivities (14 and 15, respectively) (Table 1). This indicates that
substitution in the 4’’-position of cystobactamid 507 analogues
provides only little contribution to activity.
For the synthesis of 2 and its analogues, retrosynthetic anal-
ysis revealed three units of either p-aminobenzoic acid or 5-
aminopicolinic acid derivatives linked by amide bonds. Accord-
ingly, the individual middle, C- and N-terminal rings were pre-
pared followed by the coupling of the constituents. We estab-
lished brief and efficient synthetic pathways for novel as well
as reported amino acids, which are also precursors of other
NPs[14–17] (Scheme S1). Compared to previous methods,[6, 8, 18]
the middle ring of 2 (20) was prepared in only four steps using
catechol as a starting material. Nitration of the catechol to the
3-nitro derivative 17 followed by regioselective isopropylation
at the 2-hydroxy position using a stoichiometric amount of 2-
bromopropane provided 18. ortho-Formylation of 18 with par-
aformaldehyde in MgCl2/TEA/MeCN mixture under strictly an-
hydrous conditions produced the p-nitrobenzaldehyde 19. The
latter was finally oxidized using AgNO3 under basic conditions
to yield the corresponding acid 20 (Scheme 1), the structure of
which was confirmed by X-ray crystallography (Figure S37A).
The C-terminal ring 22 was prepared by isopropylation of 3-hy-
droxy-4-nitrobenzoic acid followed by reduction of the result-
ing nitro derivative 21 via heating with iron in ethanol
(Scheme 1).
For amide coupling, three obstacles were encountered: The
free OH as an interfering group, the nonreactive carboxylic
acids, and the weakly reactive aromatic amines.[6, 8, 16, 18] We de-
veloped a straightforward strategy that could overcome these
difficulties and bypass the activation of carboxylic acids and
phenolic OH protection/deprotection.[6, 8, 16, 18] The total synthe-
sis of 2, for example, was accomplished in overall 11 steps in-
stead of 21 and 13, respectively.[8, 18] Coupling of the central
ring 20 to the C-protected C-terminal ring 22 was achieved by
heating the mixture with dichlorotriphenylphosphorane in an-
hydrous chloroform to afford dipeptide 23 (Scheme 1). After
reduction, the corresponding amine 24 was coupled with p-ni-
trobenzoic acid by using the same procedure as described
above. Reduction of the nitro substituted tripeptide 25 fol-
lowed by C-deprotection via ester saponification yielded the
amino acid 2 (Scheme 1). This synthetic procedure was broadly
applicable and enabled us to prepare a large series of peptido-
mimetics in short time with good to excellent yields
(Scheme S2–S4).
We evaluated the inhibitory activity of 2 and the most
potent gyrase inhibitors 7, 9, and 12 on the second bacterial
target of cystobactamids (topoisomerase IV) using a relaxation
assay, which assesses the effect on the conversion of a super-
coiled plasmid into a relaxed form.[5] Results indicated that 2
was not active up to 500 mm, whereas the new analogues dis-
played moderate inhibitory activities (Table 1). This demon-
strates that the modifications applied to improve the gyrase in-
hibitory activity are also valid for topoisomerase IV, which is
not surprising due to the high homology between both en-
zymes.[19]
Moreover, the same activity trend of the compounds on
both targets suggests a similar mode of action. The primary
binding site of the cystobactamids is probably located at the
gyrase–DNA interface overlapping that of the quinolone antibi-
otics.[5] To gain a deeper insight into the mode of action, we in-
vestigated whether and eventually how cystobactamids and
their analogues bind to the DNA part of the target complex.
There are two main binding modes of small molecules to DNA:
minor groove binding or intercalation.[20] Intercalation is of par-
ticular concern, as compounds that adopt this binding mode
may trigger genotoxic effects in eukaryotes.[21] We carried out
displacement titration experiments using fluorescent dyes that
show increased fluorescence upon DNA binding: Hoechst
33342 for DNA minor-groove binding and ethidium bromide
(EtBr) for intercalation. Titration of calf thymus DNA bound
Figure 6. Stability of 9 against AlbD: HPLC-MS analysis of 9 (12 mm) in phos-
phate buffer as control (A) and incubated with AlbD (24 mm) for 3 h at 28 8C
showing only traces of the cleavage product (B). Scheme 1. Synthesis of cystobactamid 507 (2).




Hoechst 33342 with cystobactamids 1 a, 1 b, and 2–15 induced
a concentration-dependent loss of fluorescence (Figure 7 A and
S39). No compound-induced fluorescence quenching was ob-
served in the absence of DNA. In the presence of EtBr, no com-
pound showed significant reduction in fluorescence (Figure 7 B
and S39). These results indicate that the cystobactamids are
able to bind to DNA utilizing the minor groove without signifi-
cant intercalation. Moreover, they reveal that the cystobacta-
mids and their analogues are a new chemical frame for minor
groove recognition besides the known family of five-mem-
bered fused and non-fused heterocyclic polyamides.[22]
Evaluation of the antibacterial activity against a panel of
Gram-positive and Gram-negative bacteria revealed that the
new compounds show up to 8- to 16-fold enhanced activities
against Gram-positive strains compared to the parent antibiot-
ic 2 (Table 2). A good correlation between the antibacterial ef-
fects and topoisomerases IIA inhibitory activities was observed.
In contrast to 1 a and 1 b,[5, 6] compound 2 and its analogues
did not show activity against E. coli wild-type, but they were
active against the efflux-deficient E. coli tolC3 mutant. This im-
plies that efflux is responsible for the inactivity toward E. coli
wild-type. Some compounds, like 7 and 12, suffered from pen-
etration issues through the Gram-negative outer membrane, as
indicated by the enhanced MIC values (eightfold) in the pres-
ence of a permeability enhancer.
Additionally, we investigated compounds 2, 7, 9, and 12 for
their phase I and II biotransformation using human liver S9
fraction. Cystobactamid 507 and all synthetic compounds dis-
played an extraordinarily high metabolic stability (t1/2>
240 min, Figure S42). Surprisingly, stability was observed for
both amide groups against peptidases as well as for the hy-
droxy groups of 2 and 12 toward conjugating enzymes. More-
over, conformational modification anti to syn, i.e. , 2 to 7 and 9
maintained the outstanding metabolic stability of the natural
compound.
Finally, to demonstrate that structure optimization of 2 can
be translated into potent hexapeptides, we picked an ana-
logue with a hydroxy group at the middle ring to keep the
general features of isolated cystobactamids.[6] Accordingly,
compound 4 was connected to the western part of the natural
compounds through l-asparagine as a simplified linker to form
the cystobactamid 919-2 analogue 16 (Scheme 2). Com-
pound 16 showed potent gyrase inhibition and antibacterial
activity on the Gram-negative E. coli wild type (Table 1 and 2).
This indicates that modification of the natural cystobactamid
919-2 using the tripeptidic cystobactamid 507 analogues is an
appropriate strategy to improve activity. Moreover, removal of
the methoxy group at the linker was tolerated, offering a new
space for further optimization.
The hexapeptide 16 was prepared via convergent synthesis
including a coupling of two tripeptide fragments ; namely, the
eastern and the western part with a linker.[23] The eastern part
was prepared as described above as C-Boc protected amino
acid 34 (Scheme 2). Synthesis of the western fragment started
Figure 7. DNA interaction of cystobactamid 507 (2): A) Concentration-depen-
dent decrease in fluorescence of Hoechst 33342 bound to calf thymus DNA
(ct-DNA, 15 mm each) upon titration with 2 ; B) no change in fluorescence of
the ct-DNA bound EtBr upon titration with 2.
Table 2. Antibacterial activities of cystobactamids 1 b, 2 and synthetic analogues.















2 n.d.[a] 64 128 64–128 >128 >128 32–64
4 64 16–32 >64 >64 >64 >64 >64
6 32 16 64 32 >64 4 2
7 8 8–16 32 16–32 >64 32 4
9 8 >64 8–16 >64 >64 16 4
12 32 8 >64 64 >64 32 4
13 8 4–8 64 32 >64 16 4
16 n.d. n.d. n.d. n.d. 1 0.25 n.d.
1 b n.d. n.d. n.d. n.d. 2 0.5 n.d.
CP[d] 0.1 0.8 0.8 0.8 0.013 0.003 n.d.
[a] Not determined. [b] DtolC3 genotype. [c] Polymyxin B nonapeptide (3 mg mL@1). [d] Ciprofloxacin.




with trityl protection of l-asparagine at the amide residue to
give 35 (Scheme 2). Reaction of 35 with p-nitrobenzoylchloride
(PNBC) under Schotten–Baumann conditions afforded the di-
peptide 36. Reduction of the nitro group to the amine 37 fol-
lowed by benzoylation yielded tripeptide 38. Coupling of the
latter to the amine 34 using Cl2PPh3 afforded hexapeptide 39.
General deprotection of 39 using TFA 15 % (v/v) in DCM yield-
ed 16 (Scheme 2).
Conclusions
We described a brief synthetic route for the natural antibiotic
cystobactamid 507 (2) and the design of new derivatives with
improved topoisomerases IIA inhibition, and antibacterial activ-
ity. SAR studies revealed the importance of the alkoxy side
chains and the irrelevance of the hydroxy group for gyrase in-
hibition. The terminal carboxy and amino/nitro moieties were
found to be necessary for activity. The molecular conformation
in solution as well as in the solid state was investigated to
deduce the conformation–activity relationship. We pioneered
the design of noncovalently bonded rigid structures through
IMHBs to disclose the bioactive conformation of 2 as the syn
form without using the classical methods of cyclization or in-
troduction of sterically demanding moieties.[24] Increase of
chemical diversity by modification of the cystobactamid 507
scaffold into a pyridine-based structure (compound 9) turned
out to make the molecule stable toward the albicidin resist-
ance factor AlbD. It was shown that the cystobactamids’ mode
of action could be, at least in part, mediated by DNA minor-
groove binding and not intercalation. An important advantage
of 2 and the novel analogues is the high metabolic stability. Ul-
timately, we demonstrated that optimization of the tripeptides
could be translated into hexapeptidic cystobactamids with im-
proved gyrase inhibition and antibacterial activity against
Gram-negative strains. It is worth mentioning that compounds
could be designed with better pharmacokinetic properties
compared to the natural compounds. Thus, this work would
be useful for the development of cystobactamids and similar
natural compounds[14–16] toward better antibiotics.
Experimental Section
Experimental procedures for the synthesis of the final compounds
and intermediates as well as their characterization, NMR spectra,
computational work, biological experiments and X-ray crystallo-
graphic data are described in detail in the Supporting Information.
CCDC 1958329 (20), 1958330 (44), 1958331 (91), 1958332 (93),
1958333 (94), 1958334 (96), and 1958335 (97) contain the supple-
mentary crystallographic data for this paper. These data are provid-
ed free of charge by The Cambridge Crystallographic Data Centre.
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